Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).

Benjamin  Levy

Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; Guardant Health; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Novartis; Novocure; Pfizer; Sanofi; Takeda

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Loxo (Inst); Merck (Inst); Turning Point Therapeutics (Inst)

Filippo  de Marinis

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAICHII SANKYO; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda

Laura  Bonanno

Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Novartis; Roche

Research Funding - AstraZeneca

Other Relationship - Advisory board: AstraZeneca; Advisory board: Bristol Myers Squibb; Advisory board: Janssen; Advisory board: MSD; Advisory board: Novartis; Advisory board: Roche; Advisory board: Takeda; Coordinating PI: AstraZeneca; Invited Speaker: AstraZeneca; Invited Speaker: Bristol Myers Squibb; Invited Speaker: Lilly; Invited Speaker: MSD; Invited Speaker: Novartis; Invited Speaker: Roche; Local PI: Arcus Biosciences Pharmamar; Local PI: AstraZeneca; Local PI: Bristol Myers Squibb; Local PI: MSD; Local PI: Ose Immunotherapeutics; Local PI: Roche; Steering Committee Member: AstraZeneca

Adrian  Sacher

Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - Amgen; Genentech/Roche; Merck

(OPTIONAL) Uncompensated Relationships - Amgen; Genentech/Roche; Merck

Quincy  Chu

Honoraria - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Genprex; GlaxoSmithKline; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Sanofi; Takeda

Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Genprex; Genprex; GlaxoSmithKline; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Takeda

Other Relationship - GlaxoSmithKline

Christina  Baik

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Natera; Pfizer; Regeneron; Takeda

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); TP Therapeutics (Inst)

Paolo  Bironzo

Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Roche; Sanofi

Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Pierre Fabre; Regeneron; Seagen

Research Funding - Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Arqule; Pfizer

Lyudmila  Bazhenova

Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Bayer; BioAtla; BMS GmbH & Co. KG; Boehringer Ingelheim; daichi; Genentech/Roche; Gilead Sciences; Janssen Oncology; Merck; Natera; neuvogen; Novocure; Pfizer; Regeneron; Sanofi; Summit pharmaceuticals; Teligene

Marcello  Tiseo

No Relationships to Disclose

Claudia  Proto

Honoraria - AstraZeneca; BMSi; MSD; Roche

Consulting or Advisory Role - AstraZeneca; Janssen; MSD; Roche; Sanofi

Research Funding - AstraZeneca (Inst); BMSi (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Roche

Cheng-Ta  Yang

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Ono Pharmaceutical

(OPTIONAL) Uncompensated Relationships - Advisory board: AstraZeneca; Advisory board: Boehringer Ingelheim; Advisory board: Lilly; Advisory board: MSD; Advisory board: Novartis; Advisory board: Ono Pharmaceutical; Advisory board: Roche; Invited speaker: AstraZeneca; Invited speaker: Boehringer Ingelheim; Invited speaker: Lilly; Invited speaker: MSD; Invited speaker: Ono Pharmaceutical; Invited speaker: Pfizer; Invited speaker: Roche; Local PI: AstraZeneca; Local PI: Boehringer Ingelheim; Local PI: Pfizer; Speaker, consultant, advisor: AstraZeneca; Speaker, consultant, advisor: Boehringer Ingelheim; Speaker, consultant, advisor: Lilly; Speaker, consultant, advisor: MSD; Speaker, consultant, advisor: Novartis; Speaker, consultant, advisor: Ono Pharmaceutical; Speaker, consultant, advisor: Pfizer; Speaker, consultant, advisor: Roche

Jonathan  Riess

Consulting or Advisory Role - Amgen; Bicycle Therapeutics; Bristol-Myers Squibb/Celgene; Catalyst Clinical Research; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Merus NV; Oncohost; Pfizer; Regeneron; Replimune

Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Kinnate Biopharma (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer; Revolution Medicines (Inst); Summit pharmaceuticals (Inst)

Travel, Accommodations, Expenses - AstraZeneca; IO Biotech

Konstantinos  Leventakos

Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Inc (Inst); Janssen Biotech (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); Novartis (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)

Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)

James ChihHsin  Yang

Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)

Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)

Research Funding - AstraZeneca (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Takeda

Lecia  Sequist

Research Funding - AstraZeneca (Inst); Delfi Diagnostics (Inst); Novartis (Inst)

Other Relationship - GRAIL

Karen  Barrett

Employment - AstraZeneca

Stock and Other Ownership Interests  - Takeda

Ryan  Hartmaier

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Patents, Royalties, Other Intellectual Property - Inventor on issued patent : US20190218618A1 (assigned to Foundation Medicine, Genentech)

Ikechukwu  Igwegbe

Employment - AstraZeneca

Wanning  Xu

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Myung-Ju  Ahn

Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN

Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN

Research Funding - YUHAN